MSL-CM180B-100μg / 询价
MSL-CM180B-500μg / 询价
MSL-CM180B-500μgx2 / 询价
Biotinylated Cynomolgus MSLN/Mesothelin Protein (Primary Amine Labeling)
Recombinant Biotinylated Cynomolgus MSLN/Mesothelin Protein (Primary Amine Labeling) is expressed from HEK293 with His tag at the C-terminus.It contains Asp296-Gly580 [Accession | XP_005590873.4 ]
The protein has a predicted MW of 33 kDa. Due to glycosylation, the protein migrates to 35-50 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Biotinylated Cynomolgus MSLN on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Cynomolgus MSLN is greater than 95% as determined by SEC-HPLC.
Immobilized Anti-MSLN Antibody, hFc Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Cynomolgus MSLN, His Tag with the EC50 of 44.0ng/ml determined by ELISA.
Mesothelin, also known as MSLN, is a protein that in humans is encoded by the MSLN gene.Cloning studies showed that the mesothelin gene encodes a precursor protein that is processed to yield mesothelin which is attached to the cell membrane by a glycophosphatidylinositol linkage and a 31-kDa shed fragment named megakaryocyte-potentiating factor (MPF). Although it has been proposed that mesothelin may be involved in cell adhesion, its biological function is not known.A knockout mouse line that lacks mesothelin reproduces and develops normally.
MSLN; CAK1; Mesothelin; MPF; MPFSMRP; SMR
(1)Adusumilli P S , Cherkassky L , Villena-Vargas J , et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity[J]. Science Translational Medicine, 2014, 6(261):261ra151-261ra151.
